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Abstract: Oriented Peptide Mixture Libraries can provide a full matrix of preferred and
disfavored amino acids at each subsite of an optimal substrate for a new proteinase. This
approach is rapid and convenient, requiring only two mixture libraries to complete the
analysis. In this paper we demonstrate an extension of this type of analysis, using a
focused library employing unnatural amino acids to probe the depth of the S1 position
in the catalytic site of the alpha secretase ADAM-10. This analysis indicates that ADAM10 will accept amino acids with substantial length and hydrophobicity (e.g. 2naphthylalanine), but suggests that the S1 site has limitations in the apparent “width” of
substituents being presented (e.g. 1-naphthylalanine; gamma branching). A highly selective and efficient
substrate for ADAM-10, with a selectivity factor of 380,000 M-1 s-1, was derived from the predicted consensus
substrate. This detailed analysis provides a starting point for the design of inhibitors of this interesting
proteinase.

Keywords: proteinase, proteinase inhibitor, proteinase substrate, ADAM-10, consensus substrate motif
INTRODUCTION
Speed and cost effectiveness are crucial considerations
during the drug discovery process. Proteases are attractive
therapeutic targets in a number of disease areas and several
important drugs are marketed for the inhibition of protease
function [1]. For research involving enzyme targets, the
ability to quickly obtain effective substrates for HTS assays
and to create inhibitors for x-ray crystallography / structurebased design is essential.
A number of techniques have been used to deduce the
substrate requirements for novel proteases, with positional
scanning [2,3], substrate phage display [4, 5], and substrate
mixture digestion being frequently cited [6,7]. Recently an
approach that makes use of Oriented Peptide Mixture
Libraries (OPML) has been described [8] and several
advantages of this approach are apparent. For OPML, the
substrate mixture is present in solution, so no artifacts from
linkage to a solid phase or presentation in a protein are seen.
Preferences for and against amino acid residues are
determined both for the primed and unprimed side of the
substrate, in contrast to positional scanning. For the OPML
approach, a full matrix of preferences for and against each
proteinogenic amino acid at each subsite is obtained rapidly,
through the use of only 2 libraries.
Typically the OPMLs are constructed to have positions
that are fully degenerate (all proteinogenic amino acids
except Cys) surrounding a sequence of orienting residues
that force binding to the active site in a common fashion for
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the full chain. Such a library may contain tens of billions of
potential substrates, but upon exposure to the enzyme for a
short period of time (typically ca. 1-5% conversion) only the
most favored substrates are processed. Separation of the
unprocessed portion of the library and sequencing from the
N-terminus give the relative amounts of each residue found
at each position in the processed pool of peptides. This
matrix of data provides the relative favoring or disfavoring
of each amino acid residue at that position in an optimal
substrate.
The experiment is carried out as a two-step process [8].
First a fully degenerate, N-terminally blocked mixture
library (Ac-X-X-X-X-X-X-X-X-NH2; where X represents 19
proteinogenic amino acids, lacking Cys) is incubated with
the enzyme. These peptide libraries are obtained by using
isokinetic mixtures of amino acids being explored at each
position of the substrate peptide [9]. Cleavage of the peptide
at any position then opens up a site for N-terminal Edman
sequencing. The first cycle provides the P1’ site preference
information, the second cycle provides the P2’ site
population, etc. In the second step, an OPML is generated
using the primed side information, while full degeneracy is
maintained on the unprimed side [i.e. NH2-X-X-X-X-O-O-OO-Lys(Biotin)-NH2; where O represents a fixed, orienting
residue]. This OPML has an unblocked amino terminus, so
that Edman sequencing can be carried out, but has a biotin
residue at the C-terminus so that uncleaved library members
and the C-terminus of cleaved substrates can be removed by
streptavidin chromatography. Thus following the enzyme
incubation with the OPML, the mixture can be run through
a streptavidin column and the flow through will contain
only the amino terminal residues of substrates cleaved by the
enzyme. Edman sequencing of this mixture for the library
shown above yields P4 preference information in the first
© 2004 Bentham Science Publishers Ltd.
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Fig. (1). Matrix of ADAM 10 cleavage of the Ac-X8 library. An acetylated X8 library was incubated with 60 nM human ADAM 10 for 9
hrs at 37°C as described. The normalized data is presented for each amino acid (top row) at each prime-side position (left column). The
preferred amino acids are printed in Italic.
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Fig. (2). Complete matrix for human ADAM-10. Human ADAM-10 was incubated with the focused library (NXXXXLKXXK-biotin) for
24 hours at 37°C as described. The uncleaved and prime side of the substrate was removed with streptavidin beads and the remaining
peptides were subjected to n-terminal sequencing. In the left four columns, indicating the non-primed side of the peptide, the
normalized data is presented next to each amino acid for each substrate position (top row). Amino acids chosen for the optimal
substrate are shown in Italic. The data from Figure 1 (Primed side) has been reconfigured and placed next to the non-primed side data
so that the complete Consensus Matrix™ can be visualized. The nomenclature of Schechter and Berger [29] is used to denote
positions in substrates at the amino terminal (unprimed) and carboxy terminal (primed side) of the cleavage site.

cycle, P3 preference information in the second cycle, etc.
The data so obtained (Figure 1) is then assembled into the
Consensus Matrix ™ of amino acid preference information
for each subsite in the proteinase (Figure 2).

The OPML approach has been used successfully to
determine substrate subsite preferences for a wide variety of,
kinases and protein binding domains [10-12], and recently
has been extended to proteases [8]. This approach provides a
matrix of information describing the preferred and disfavored
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residues at each position of the substrate. Hence, one can
rapidly and simply, using a minimum number of libraries,
obtain a large amount of detailed structural information
regarding the enzyme target. This is valuable not only for
designing substrates and inhibitors for the enzyme, but also,
when used in combination with matrix information of
related enzymes, for providing selectivity information. This
powerful tool focuses on the positions and modifications
necessary to give the enzyme selectivity for a particular
molecule being designed, be it as a drug or tool. To date,
this technology has primarily utilized the 20 proteinogenic
amino acids. In this paper we report an important extension
of this technology wherein a set of structurally diverse,
unnatural amino acid probes is used to provide more detailed
information regarding a particular binding pocket of interest.
As an example, we report a study of the active site
requirements of the metalloproteinase ADAM-10. The
ADAM family (A Disintegrin And Metalloproteinase) shares
structural homology to certain snake venoms and certain of
its members appear to play major roles in modifying the
surface exposure of critical signaling molecules [13]. Human
ADAM-10 is a 59 kDa, single chain metalloproteinase
[14,15] initially isolated as a putative Tumor Necrosis
Factor-α Convertase (TACE). Although the physiological
TACE now is felt to be ADAM-17 [16], it has been
suggested that ADAM 10 may play a major role as a
“sheddase”, causing release of proteins from the cell surface
[17]. Although some potential natural substrates have been
suggested [18,19], no optimal in vitro substrate has been
reported.
In this paper we have analyzed the active site preferences
for and against each proteinogenic amino acid and identified
a suitable peptide substrate for ADAM-10. We then extended
these studies to further probe the size of the P1 binding
pocket through the use of OPML containing unnatural
amino acids.
EXPERIMENTAL PROCEDURES
Reagents
Fmoc-protected amino acids, peptide synthesis resins,
and coupling reagents were purchased from Novabiochem
(San Diego, CA) or Chem-Impex International (Woodale,
IL). PalPeg resign was purchased from Applied Biosystems.
Other peptide synthesis reagents were purchased from the
Sigma-Aldrich Corporation (St. Louis, MO). Solvents for
synthesis and HPLC were JT Baker Brand. Activated human
ADAM-10 was purchased from R&D Systems
(Minneapolis, MN). Streptavidin beads are from Upstate
Biotechnology (Lake Placid, NY). All other Chemicals for
making buffers are obtained from Sigma-Aldrich
Corporation (St. Louis, MO). All Edman (Procise)
sequencing and 433 synthesis reagents are from Applied
Biosystems, Inc. (Foster City, CA).
Library Synthesis
All fully degenerate libraries, focused libraries and
unnatural amino acid libraries were synthesized using an
ABI 433A Peptide SynthesizerTM (Perkin Elmer-Applied
Biosystems) on a 0.25 mmole scale using Rink Amide
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MBHA resin (Nova Biochem). The degenerate positions,
‘X’, were attached using experimentally determined
isokinetic mixtures of 19 natural amino acids (Cys deleted)
containing the following ratios of Fmoc amino acids: 1.0
(Ala, Gly, Leu, Met); 1.3 (Phe, Tyr(t-Bu)); 1.7 (Asn(Trt),
Asp(t-Bu), Glu(t-Bu), Gln(Trt), Lys(t-Boc), Pro); 2.0
(Arg(Pmc), His(Trt), Ile, Val, Ser(t-Bu), Thr(t-Bu)); 2.3
(Trp(t-Boc)).
For each coupling step 4 equivalents (1.0 mmole) of
isokinetic mixture or a single amino acid was weighed into
an Applied Biosystems Amino Acid CartridgeTM (ca. 440
mg/cartridge). Each library was made using the standard
FastMoc 0.25 mmol chemistry protocol with Single Couple
protocols provided in the Applied Biosystems software.
Acetylation of the degenerate libraries was conducted using
0.3 M N-acetylimidazole for 3 hours at room temperature.
Complete acetylation was determined through ninhydrin
testing. The focused libraries were synthesized in the same
manner with the exception of the addition of the first amino
acid. Fmoc-Lys(biotinyl)-OH (ChemImpex CAT # 4988)
was coupled manually to the resin using 1.0 mmole amino
acid and HBTU with 2.0 mmole DIEA in DMF. The
reaction was done in a 10 mL syringe with a polystyrene frit
and allowed to shake overnight at room temperature. The
resin was then loaded onto the 433 Synthesizer and the
remaining amino acids were added automatically.
The unnatural amino acid focused library was synthesized
using the same procedures as the focused libraries. The ratios
of the unnatural Fmoc-protected amino acids in the
isokinetic mixture were: 1.0 (Phe, hPhe); 1.1 (Cha); 1.2
(Nal(2)); 1.3 (Bip, Phg); 1.4 (1-Nal, Chg).
Once the resin synthesis was complete, the libraries were
cleaved from the solid support and deprotected using a
TFA/anisole/water/triisopropyl silane (95:2:2:1) solution
and allowed to stand for four hours with occasional stirring
[20]. The mixture was filtered and the resin washed with
TFA (2 X 2 mL). The combined eluant was cooled and the
libraries were then precipitated with Et2O. The mixture was
centrifuged and the Et2O decanted from the precipitate. The
precipitate was triturated with Et2O two more times. After
the final Et2 O wash, the libraries were dried under N2 ,
dissolved in 2 mL HOAc and lyophylized. The lyophilized
solid was used directly in the enzyme incubations.
Substrate Synthesis
PalPeg resin (4.5 g) was put into a 50 ml syringe with a
frit on the bottom, washed 3X with DMF and 3X with
CH 2Cl2. The Fmoc group was removed with three washes
with 20% PIP/DMF and tested with ninhydrin. Fmoc-Arg(Pbf)-OH was added to the resin (2.6 g) using HBTU and
DIEA and shaken for 1 hour at room temperature.
Deprotection was performed as above. Fmoc-Lys(Dabcyl)OH (2.5 g) was added using HBTU and DIEA and the
reaction was shaken overnight at room temperature. A
ninhydrin test confirmed the coupling. The resin was then
placed on a Millipore 9050 peptide synthesizer to couple the
amino acids up to the Glu-EDANS automatically, using
standard protocols. The Glu-EDANS and final R residue
were added manually as above. The peptide was cleaved
from the resin with 20% PIP/DMF and processed as above
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(library synthesis). Each peptide was purified by rp HPLC
using a CH3CN/0.05% TFA gradient system to > 90%.
Enzyme Incubation for Matrix Determination
The reaction mixtures containing 3 mg/ml of peptide
library solutions (1-2 mM) and 60 nM of ADAM 10 in 50
mM HEPES, pH 7.5, 5 μM ZnCl2 , 0.01% brij-35 were
incubated at 37o C. 20 μL of aliquots were taken out and
quenched by 3 μL of 5% TFA at a series of time points of 0
min, 10 min, 30 min, 1 hr, 2hr, 4 hr, 9hr, and 24hr.
For the N-terminal acetylated, totally degenerate peptide
libraries, 10 μL aliquots from certain time points (1-5 %
cleavage) were sequenced.
For the biotin-containing, focused libraries, 1 μL of the
aliquot at different time points was sequenced for 1-2 cycles
to determine the percentage of cleavage. The appropriate
samples containing 3-5% cleavage were incubated with
streptavidin beads to remove the C-terminal cleaved product
and uncleaved peptide. Briefly, 20 ul of the stopped enzyme
reaction was incubated with 400 ul washed (3X PBS and 3X
NH4 HCO3) streptavidin beads with 400 μL NH4 HCO3 for
one hour at 4°C. Following incubation, the reaction was
transferred to BioRad disposable columns (Cat #731-1550)
and the flowthrough was collected. Each column was washed
4 X with 150 ul NH4 HCO3. The flowthrough and washes
for each sample were combined and dried on a SpeedVac,
washed 2X with 100 ul 10% HOAc, and dried between each
wash. Following the final wash, the samples were
resuspended in 10 μL of sequencing buffer (20% CH3CN,
0.1% TFA) and the entire sample was loaded onto the
sequencer.
Sequencing
Samples were sequenced using Edman chemistry on an
Applied Biosystems Procise 494 Protein Sequencer. Peptide
libraries (typically 200 to 500 pmol) were loaded on the
sequencer according to standard protocols for the instrument.
HPLC purification of each cycle was carried out from 0-48%
buffer B (CH 3 CN/2-Propanol; Applied Biosystems
#401570) at 1% per minute. For the peptide libraries
containing unnatural amino acids, a longer gradient was
developed. This gradient was extended to 51% buffer B at
1% per min. The flask cycles were also modified using
standard Procise protocols to ensure enough equilibration
time for HPLC separation.
Data Analysis
The relative preference for each amino acid in a given
cycle (A(ij)) was calculated by dividing the amount of that
particular residue (in pmol) after digestion (D(ij)) by the
relative amount of that particular amino acid, at that
particular position, in the starting mixture library (R(ij)).
This can be expressed by: (A(ij)=D(ij)/ R(ij)).The data was
then normalized to the total number of amino acids used in
each X position, (An(ij)), by the equation:
(An(ij)=(A(ij)/sum(Aij)) x total number of AA). Sum A(ij)
equals the sum of all amino acids A(ij)s at that position.
The values grater than one indicate a preference above the
average [21].
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For the unprimed side an additional value was added to
the equation (B(ij)) to account for the remaining undigested
library following streptavidin purification. A(ij)=[D(ij)B(ij)]/R(ij). The data was then normalized as above.
For the non-natural amino acid containing peptide
libraries, HPLC peak area was used.
Enzyme Kinetics
The ADAM-10 enzyme solution (20 nM in 25 mM
TRIS pH 9.0, 2.5 uM ZnCl2, 0.005% Brij-35) and substrate
dilutions (10-160 uM in above buffer) were equilibrated to
37°C for 10 minutes prior to mixing. ADAM-10 (10 nM)
was incubated with the consensus substrate or the ADAM-17
substrate at various concentrations (5-80 uM) in a Molecular
Devices fMax Gemini 96-well plate reader. The reader was
set to Ex 350 nm/ Em 490 nm, kinetic read every 9 seconds
for 20 minutes, mixing between reads. Data was analyzed
using the SoftMax Pro software and curves were generated
using the Michaelis Menten equation with KaleidaGraph
software. Substrate concentrations were corrected for peptide
content, determined by amino acid analysis.
RESULTS
Matrix Determination
Initial screening of an Ac-XXXXXXXX-NH2 library
(where X = 19 natural L-amino acids excluding Cys) with
ADAM-10 gave a matrix shown in Figure 1. The Ac on the
N-terminal blocks Edman sequencing of the uncleaved
peptides in the mixture and of the P-side of the cleaved
substrates. This allows only the P’ side of the most optimal
substrates (first 1-5% cleaved) to be available for sequencing.
A strong preference for Leu at P1’ and a weaker preference for
Lys at P2 ’ can be seen in the figure. There was limited
amino acid selectivity at positions P3’ and P4’ as indicated
by each amino acid being represented by a number close to
1.0 (normalized data), indicating that such amino acid
residues are neither favored nor disfavored at this position in
a good substrate. Thr was not taken into consideration for
these experiments due to a large contaminating buffer peak
co-eluting at the Thr position.
Based on this result, a focused library NH2 X X X X LKXXK(biotin)-NH2 (where X = 19 natural L-amino acids
excluding Cys) was synthesized and incubated with ADAM10 as described. Following removal of the C-terminal
fragments and uncleaved peptides using streptavidin beads,
the resulting matrix for positions P4-P1 can be seen in
Figure 2. At the P1 site a preference can be seen for Tyr. At
the P2 position, Gln is the most represented amino acid.
The P3 position shows a weak preference for Tyr, Ala and
Pro. Since Pro is generally not tolerated in most positions,
when it is tolerated, as identified in position P3 for ADAM
10, we feel it is a good idea to use it in the peptide to help
orient the peptide in the binding site. Finally, at the P4
position, Arg is preferred.
ADAM 10 Consensus Substrate Analysis
To generate the consensus peptide, we brought together
the information from both the P- side and the P’. Because
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Substrate

Km (uM)

Vmax uM/sec

kcat/Km M-1 s-1

ADAM-10

10.24

0.034

380,000

ADAM-17

29.07

0.009

36,000

Fig. (3). Determination of Km and Vmax for ADAM 10 consensus sequence. A peptide representing the determined consensus
sequence for ADAM-10 (NH2-D-Arg-Arg-Glu(Edans)-Arg-Pro-Gln-Tyr-Leu-Lys-Ser-Ser-Lys(Dabcyl)-Arg-NH2) was compared to a
known ADAM-17 substrate (NH2-Arg-Glu(Edans)-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Lys(Dabcyl)-Arg-NH2). Human ADAM 10 (20 nM)
was incubated with each substrate at varying concentrations as described. The Km and Vmax were determined by plotting the
Michaelis-Menten equation using KelidaGraph software.

there was no particular selectivity determined in the matrix
for positions P3’ and P4’, and considering there are
similarities between ADAM-10 and ADAM-17 [15,22], we
chose to use the relatively innocuous amino acid Ser for
those positions in our substrate peptide. Polar residues
would be preferred since we interpret the lack of selectivity
at these positions as their being present in the bulk aqueous
phase when bound to the enzyme. The known substrate for
ADAM-17 contains Ser at positions P3’ and P4’ [23].
A Peptide Containing the Putative Consensus Sequence
for ADAM-10
(NH2-D-Arg-Arg-Glu(Edans)-Arg-Pro-Gln-Tyr-Leu-LysSer-Ser-Lys(Dabcyl)-Arg-NH 2 ) was synthesized and
subjected to a series of kinetic analyses (Figure 3). For
comparison, a known substrate for ADAM-17 (NH2-ArgGlu(Edans)-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Lys(Dabcyl)Arg-NH2) (Bachem #M-2155) was characterized. The Km for
the ADAM-10 substrate was determined to be 10 uM as
compared to almost 30 uM for the ADAM-17 substrate. The
Vmax for the ADAM 10 substrate was determined to be
0.034 uM/sec yielding a “selectivity factor” (kcat/Km) of
380,000 M-1s-1. This can be compared to the Vmax for the
ADAM-17 substrate of 0.009 uM/sec which yields a
selectivity factor of 36,000 M-1s-1. By this analysis, ADAM
10 has a 10 fold greater selectivity for the ADAM-10
substrate identified using the OPLM method over the
ADAM 17 substrate.
Unnatural Amino Acid Library Design
Having determined that the substrate generated from the
ADAM 10 matrix was an efficient substrate (kcat/Km =
380,000 M-1s-1), we were interested in probing further the
character of favored P1 substitutions in ADAM-10. The

identification of Tyr as the favored residue at P1 suggested
that the S1 pocket (site in the enzyme that interacts with the
P1 position of the substrate peptide) might be a pocket with
significant depth. Since such pockets may have great
significance for inhibitor design, we decided to explore the
nature of the S1 pocket using an OPML with a diverse set of
unnatural lipophilic and aromatic amino acids at the P1
position.
Since the technology being used to probe the P1 binding
site relies on Edman sequencing of the digested library
mixture, the unnatural amino acids chosen need to be
identifiable in standard sequencing protocols. Hence, the
choice of amino acids was based on a balance of structural
diversity and their ability to be separated in the HPLC step
of the sequencing protocol. The chosen set of unnatural
amino acids is shown in Figure 4. As can be seen, they
serve as probes of depth [Phe, hPhe, Bip, Nal(2), Phg],
width [Nal(1), Cha] and the need for aromaticity (either
specific interaction or “flatness”) [Cha, Chg]. From our
experience with isokinetic mixtures of natural amino acids,
we approximated the amount for each unnatural amino acid
in the isokinetic mixture. Having an exact equimolar ratio
was not essential since the unprocessed library is used as a
control and we report the ratio of a particular amino acid in
the cleaved library sample to its corresponding level in the
unprocessed library. Hence, preferred and disfavored amino
acids are reflected properly as the ratio to their abundance in
the unprocessed library.
The oriented library made using these unnatural amino
acid probes was:
Asp-Arg-Pro-Glu-X-Leu-Arg-Ser-Ser-Lys(Biotin)-NH2,
where X represents the isokinetic mixture of amino acids
shown in Figure 4.
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Fig. (4). Set of unnatural amino acid structural probes.

Fig. (5). Sequencing at position P1 of library mixture before (A) and after 10 min. incubation with enzyme (B). The focused library
Asp-Arg-Pro-Glu-X-Leu-Arg-Ser-Ser-Lys(Biotin)-NH2 was synthesized where X represents an isokinetic mixture of the amino acids
shown in Figure 4. This library was incubated with ADAM-10 for 30 minutes at 37 °C followed by purification and sequencing as
described. The cleaved library is represented in the B profile, while the starting library is represented in the A profile.
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This library was subjected to the standard enzyme
cleavage protocol and processed in the same way as the
previously described samples.
P1 Preference Determination Using the Unnatural Amino
Acid Library
ADAM-10 was incubated with the above focused,
oriented library for 1 min. Following removal of the
uncleaved peptides and the C-terminal fragments using a
streptavidin column the sample was sequenced as described.
The HPLC profile is shown in Figure 5B for the cleaved
library and in Figure 5A for the uncleaved, reference library.
The peak area was determined for each unnatural amino acids
in both profiles (data not shown). The ratio of peak area B/
peak area A was determined and is shown in Table 1. Amino
acids that were strongly favored in the P1 position, as
indicated by a value of greater than 1, include Phe and hPhe.
Na1(2) was also favored, although to a lesser extent. The
amino acids that were tolerated include Cha, Phg and Bip.
The amino acids that were strongly disfavored were the 1Nal and Chg.
Table 1. Preference Ratios of the Amino Acids at the P1
Position of the Oriented Mixture Substrate. Area
Under the Curve for each Unnatural Amino Acid
Shown in Figure 5 was Determined. The Difference
was Calculated by the Ratio Area Peak B/Area Peak
A.
FAVORED
Phe

hPhe

2-Nal

2.95

1.72

1.29

Cha

Phg

Bip

0.67

0.48

0.47

TOLERATED

DISFAVORED
1-Nal

Chg

0.25

0.17

DISCUSSION
It is clear that the OPML analysis of proteinase substrate
requirements can be used to accelerate inhibitor drug
discovery programs. As is apparent from the data in Figures
2 and 3, this approach can provide a comprehensive analysis
of proteinase active site preferences very rapidly with the use
of only two libraries. The consensus substrate motif is read
off the tops of the columns (most abundant, i.e. most
favored residues at each subsite) in the Consensus Matrix™.
Several peptide substrates, incorporating residues in
positions of high selectivity near the top of the columns, are
generally made to investigate fine tuning of the behavior of
the substrate for choice of a reagent for HTS assay
development. The substrate chosen for synthesis in this
study has a very high selectivity factor (380,000 M-1s -1),
suggesting that it is likely to be an excellent substrate for
assay development. The Consensus Matrix™ can also be
used to design selective substrates, since it also indicates
which residues are strongly disfavored at critical subsites.
Judicious choice of residues allowed in a subsite for one
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proteinase, but disfavored for another proteinase can be used
to derive high selectivity.
The OPML analysis is also used to design first
generation proteinase inhibitors. Since there are well
accepted methods for going directly from substrate
identification to peptide inhibitor design for each of the four
major classes of proteinases [1], the information in the
Consensus Matrix™ can be used to rapidly generate first
generation inhibitors for use in target validation and x-ray
crystal structure studies.
The physiological role and substrates for ADAM-10 are a
subject of much scientific interest. Although ADAM-10 was
originally isolated as a putative TNF convertase, ADAM-17
now is generally accepted to play this role. Mice with an
ADAM-10 knockout genotype die in day 9.5 of
embryogenesis due to multiple defects in the CNS and
cardiovascular system [24]. ADAM-10 and –17 are felt to
play a key role in the activation of the Notch signaling
pathway [25] and in the benign processing of the Amyloid
Precursor Protein through “alpha secretase” cleavage at a site
near the outer cell membrane [26].
Metalloproteinases typically exhibit strong selectivity
dependence on the residue at position P1’ [27]. The presence
of Leu or Tyr is generally taken as evidence of a shallow or
deep S1’ site, respectively [28]. For ADAM-10 we find Leu
preferred and Tyr accepted in the P1’ position. We were
intrigued to find Tyr favored at P1 and took it as an
indication that P1 might be a deep pocket. In order to
investigate the characteristics of this subsite we studied a
focused OPML that incorporated a mixture of unnatural,
hydrophobic amino acids at the P1 position. The amino acid
mixture incorporated in P1 was chosen to test the depth and
width of S1 binding subsite (Figure 4; discussed above).
Pth-amino acid elution conditions were developed which
allowed quantitation of these individual amino acids in a
single sequencing run (Figure 5). As outlined in Table 1,
amino acids of considerable length could be accommodated
in S1 (hPhe, Nal(2), Bip), but wide or “fat” amino acids
(e.g. Nal(1) and Cha; Chg, respectively) were not accepted.
Additional probing of this or other subsites with amino acid
mixtures designed to ask other questions (e.g. electron rich
or poor heterocyclic side chains) can be visualized readily.
This type of information would be valuable in the design of
inhibitors of ADAM-10.
We have provided another illustration of how the OPML
approach [8, 30] to the analysis of the optimal substrate
requirements of a new enzyme can be executed very rapidly
with only two libraries, providing a very powerful matrix of
information for substrate and inhibitor design. We have
further shown that the approach can be extended to the use of
unnatural amino acid mixtures for detailed probing of active
site binding character. The rapid development of a suitable
HTS assay for a novel protease, as well as inhibitors for
target validation and x-ray studies, provides a comprehensive
approach for the acceleration of drug discovery.
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[12]

Bip

=

3-(4-biphenyl)-L-alanine

Cha

=

3-cyclohexyl-L-alanine

Chg

=

L-cyclohexylglycine

hPhe

=

L-homophenylalanine

HTS

=

high throughput screening

1-Nal

=

3-(1-naphthyl)-L-alanine

2-Nal

=

3-(2-naphthyl)-L-alanine

Phg

=

L-phenylglycine

Fmoc

=

Fluorenylmethyloxycarbonyl

DIEA

=

Di-iso-propylethyl amine

HBTU

=

2-(1H-benzotriazole-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate

DMF

=

N,N-dimethylformamide

FRET

=

Fluorescence resonance energy transfer

[19]

TFA

=

Trifluoroacetic acid

[20]
[21]
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